900 million oral hypoglycemic drug Jiangsu pharmaceutical company's first review

A few days ago, the official website of the State Food and Drug Administration showed that the voglibose tablets of Suzhou Sinochem Pharmaceutical Industry passed the consistency evaluation, which is the first in China

Source: official website of the State Food and Drug Administration

Voglibose is an oral hypoglycemic agent that inhibits the disaccharide hydrolase (α-glucosidase) that breaks down disaccharides into monosaccharides in the intestines, thereby delaying the digestion and absorption of sugars, thereby improving meals After hyperglycemia

The voglibose preparations currently on the market in China include voglibose tablets/dispersible tablets/chewable tablets, voglibose capsules and so on

The terminal of public medical institutions in China is the "main battlefield" of voglibose.

Voglibose consistency evaluation report status (including new classification report production)

Source: Meinenet MED2.

Jiangsu Chenpai Pharmaceutical has exclusively submitted a supplementary application for the consistency evaluation of voglibose dispersible tablets, which is currently under review and approval; 3 companies have applied for the consistency evaluation of voglibose tablets.

Over-evaluation status of Suzhou Sinochem Pharmaceutical Industry

Source: Meinenet MED2.

Meinenet data shows that Suzhou Sinochem Pharmaceutical Industry has 5 products that have passed or deemed to have passed the consistency evaluation, among which voglibose tablets are the first oral hypoglycemic drug to be reviewed

Source: Meinenet database, official website of the State Drug Administration, etc.

Note: Meinenet China's urban entity pharmacy terminal competition pattern database is an enlarged version of the urban entity pharmacy database that covers 293 cities and above cities across the country (excluding county and rural entity pharmacies), and continuously monitors all categories